Literature DB >> 27868024

Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies.

Amy S Codd1, Saly Al-Taei1, Zsuzsanna Tabi1.   

Abstract

Year:  2016        PMID： 27868024      PMCID： PMC5104641          DOI： 10.21037/atm.2016.10.30

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits.

Authors:  Se-Yeong Oh; Hyun Jung Kang; Young Sook Kim; Hyunggee Kim; Young Chang Lim
Journal:  Eur J Cancer       Date:  2012-07-06       Impact factor: 9.162

2.  Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells.

Authors:  Sudha Krishnamurthy; Zhihong Dong; Dmitry Vodopyanov; Atsushi Imai; Joseph I Helman; Mark E Prince; Max S Wicha; Jacques E Nör
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

Review 3.  Immunology of cancer stem cells in solid tumours. A review.

Authors:  Cristina Maccalli; Andrea Volontè; Carolina Cimminiello; Giorgio Parmiani
Journal:  Eur J Cancer       Date:  2013-12-12       Impact factor: 9.162

4.  Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Authors:  Lisa K Spary; Josephine Salimu; Jason P Webber; Aled Clayton; Malcolm D Mason; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

5.  Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.

Authors:  Carmen Visus; Yangyang Wang; Antonio Lozano-Leon; Robert L Ferris; Susan Silver; Miroslaw J Szczepanski; Randall E Brand; Cristina R Ferrone; Theresa L Whiteside; Soldano Ferrone; Albert B DeLeo; Xinhui Wang
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

6.  CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.

Authors:  Yunqin Lee; June Ho Shin; Michelle Longmire; Hua Wang; Holbrook E Kohrt; Howard Y Chang; John B Sunwoo
Journal:  Clin Cancer Res       Date:  2016-02-10       Impact factor: 12.531

7.  Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.

Authors:  Alexander D Boiko; Olga V Razorenova; Matt van de Rijn; Susan M Swetter; Denise L Johnson; Daphne P Ly; Paris D Butler; George P Yang; Benzion Joshua; Michael J Kaplan; Michael T Longaker; Irving L Weissman
Journal:  Nature       Date:  2010-07-01       Impact factor: 49.962

8.  Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines.

Authors:  Tian Liao; Andreas M Kaufmann; Xu Qian; Voramon Sangvatanakul; Chao Chen; Tina Kube; Guoyou Zhang; Andreas E Albers
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-23       Impact factor: 4.553

9.  Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.

Authors:  Rena Morita; Satoshi Nishizawa; Toshihiko Torigoe; Akari Takahashi; Yasuaki Tamura; Tomohide Tsukahara; Takayuki Kanaseki; Alice Sokolovskaya; Vitaly Kochin; Toru Kondo; Satoshi Hashino; Masahiro Asaka; Isao Hara; Yoshihiko Hirohashi; Noriyuki Sato
Journal:  Cancer Sci       Date:  2014-02-24       Impact factor: 6.716

10.  PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy.

Authors:  Anne-Marit Sponaas; Neda Nejati Moharrami; Emadoldin Feyzi; Therese Standal; Even Holth Rustad; Anders Waage; Anders Sundan
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.